Specialty Pharmacy

Scientists map pathological progress of disease.

Spontaneous cure achieved in first person documented with WHIM Syndrome.

Annual rate of primary tumor removal has decreased since 1988.

Cells found to hijack vitamin D receptors to repair damage caused by therapy.

Raulo Frear, PharmD, general manager of OmedaRx, discusses the ramifications of biosimilars hitting the US market.

Trend reflects growing tobacco epidemic among women.

Biological process may lead to failure of embryo to attach to uterine wall.

Avella Specialty Pharmacy announced today that it has been selected by Pfizer as one of the limited groups of specialty pharmacies authorized to distribute the manufacturer's breakthrough breast cancer drug-Ibrance (palbociclib)-which has just received fast-tracked approval from the FDA.

Antiretroviral therapy has led to remarkable improvements in HIV-infected individuals. By suppressing HIV RNA to

Efficacy and safety demonstrated in models of aggressive leukemia.

Entry of web site into particular market correlates with increase in new cases.

Changes address concerns that the process to access investigational drugs was too difficult.

The first comprehensive consulting solution for integrated specialty drug management.

A recent study has identified how chronic hepatitis infection can pave the way to liver cancer.

Amgen has announced positive results of a phase 3 study evaluating its investigational drug, ABP 501, a biosimilar candidate to AbbVie's fully human anti-tumor necrosis factor alpha monoclonal antibody, adalimumab, in patients with moderate-to-severe rheumatoid arthritis.

Death risk twice as high for survivors who smoke compared with non-smokers.

Use of appropriate technology in the pharmaceutical supply chain can help reduce costs to organizations and improve care for patients.

Avella Specialty Pharmacy announced today that it has been selected by GlaxoSmithKline as one of a select group of pharmacies authorized to continue to distribute Benlysta, a medication approved by the FDA for the treatment of systemic lupus erythematosus in patients who have previously received other therapies.

The news of Margaret A. Hamburg, MD, resigning from her long-standing post as FDA Commissioner stirred memories of her success with improving access to emergency contraception, but more so her struggles with regulating drug compounding following a deadly fungal meningitis outbreak traced to a compounding pharmacy's tainted drugs.

Symptoms include airflow obstruction, bronchial hyperresponsiveness, and airway inflammation.

Phase 3 trial for polycythemia vera drug significantly improved hematocrit control without the need for phlebotomy.

Progression-free survival improved from treatment during phase 3 trial.

As the role of the pharmacist continues to expand to meet the health care needs of patients nationwide, Parata Systems and Pharmacy Times are gearing up for the sixth annual program recognizing outstanding pharmacists, technicians, student pharmacists and industry advocates. The NextGeneration Pharmacistâ„¢, the industry's leading national awards program, begins accepting nominations today for these prestigious awards.

See a new technique to treat severe asthma.

Research identifies how tumors resist current treatments.

Treatment was previously designated as a breakthrough therapy for bladder cancer.

The FDA today granted accelerated approval to a drug that treats breast cancer in postmenopausal women by attacking molecules that promote cancer cell growth.

Amgen and its subsidiary, Onyx Pharmaceuticals, have submitted a supplemental New Drug Application (sNDA) to the FDA for their proteasome inhibitor, carfilzomib (Kyprolis), in the hopes of expanding the drug's indication to include patients with relapsed multiple myeloma who have received at least 1 prior therapy.

An examination of the pathophysiology of asthma.

Thomas Morrow, MD, chief medical officer at Next IT, discusses the future of patient care with the use of virtual health assistants.